DANBURY, Conn., March 20 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) today announced that Gerard Michel, Chief Financial Officer, Vice President of Corporate Development and Treasurer of Biodel, will present a corporate update at the BioCentury Future Leaders Conference on Thursday, March 27, 2008 at 3:00 p.m. Eastern Time. The conference will be held at the Millennium Broadway Hotel and Conference Center in New York City.
Interested parties may access a link to a live webcast of the corporate presentation in the investor relations section of Biodel's website at http://www.biodel.com. An archive of the presentation will be available at the same location.
About Biodel Inc.
Biodel Inc. is a specialty biopharmaceutical company focused on the
development and commercialization of innovative treatments for endocrine
disorders, such as diabetes and osteoporosis. Biodel's product candidates
are developed by using VIAdel(TM) technology, which reformulates existing
FDA- approved peptide drugs. The Company's lead product candidate,
VIAject(TM), is an ultra rapid-acting injectable meal-time insulin in
development for use by patients with Type 1 or Type 2 diabetes. VIAject(TM)
is currently being tested in two pivotal Phase III clinical trials.
Biodel's pipeline also includes VIAtab(TM), a sublingual tablet formulation
of insulin in the Phase I stage of clinical testing, and two pre-clinical
osteoporosis product candidates. For further information regarding Biodel,
please visit the Company's website at http://www.biodel.com.
|SOURCE Biodel Inc.|
Copyright©2008 PR Newswire.
All rights reserved